B. Clemmesen

The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study

Pernille Ravn, B. Clemmesen, B.J. Riis et al. · Bone · 1996 · 151 citations

Bone Markers, Orthopaedics, Bone Mass +5

Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women

Pernille Ravn, B. Clemmesen, Claus Christiansen · Bone · 1999 · 148 citations

Bone Disease, Biochemical Markers, Bone Health +13

A 2-Year Phase II Study with 1-Year of Follow-up of Risedronate (NE-58095) in Postmenopausal Osteoporosis

B. Clemmesen, Pernille Ravn, B. Zegels et al. · Osteoporosis International · 1997 · 74 citations

Bone Disease, Bone Health, Medicine +8

Changes in Biochemical Markers and Bone Mass After Withdrawal of Ibandronate Treatment: Prediction of Bone Mass Changes During Treatment

Pernille Ravn, J. O. Christensen, Melissa J. Baumann et al. · Bone · 1998 · 68 citations

Bone Disease, Biochemical Markers, Bone Health +9

High Bone Turnover is Associated with Low Bone Mass and Spinal Fracture in Postmenopausal Women

Pernille Ravn, Marianne Rix, Helle Frost Andreassen et al. · Calcified Tissue International · 1997 · 55 citations

Bone Disease, Bone Health, High Bone Turnover +9